Anixa Biosciences Inc: directors' dealings · United States · SEC (Form 4)

About Anixa Biosciences Inc

Anixa Biosciences Inc. is a U.S.-based biotechnology company listed on the NASDAQ under the ticker ANIX. For French-speaking investors, it fits the profile of a clinical-stage oncology biotech rather than a commercial pharmaceutical company: the investment case depends primarily on scientific execution, clinical readouts, regulatory progress, and strategic partnerships. The company is headquartered in San Jose, California, placing it in one of the most active U.S. biotech and venture capital ecosystems. Anixa’s corporate roots date back to its incorporation in Delaware in 1982, and the company later rebranded as Anixa Biosciences in 2018 as it sharpened its focus on cancer-related technologies. ([anixa.com](https://www.anixa.com/?utm_source=openai)) Anixa’s business model is built around highly focused oncology innovation. Its therapeutics portfolio includes an ovarian cancer immunotherapy program based on a novel CAR-T approach known as CER-T, developed in collaboration with Moffitt Cancer Center. In parallel, the company is advancing a vaccine platform aimed at the prevention and treatment of breast cancer, especially triple-negative breast cancer, as well as ovarian cancer, through collaborations with Cleveland Clinic. Management also describes additional “retired tissue specific protein” vaccine programs that could eventually be expanded into other hard-to-treat cancers such as lung, colon, and prostate cancer. ([anixa.com](https://www.anixa.com/about?utm_source=openai)) From a competitive standpoint, Anixa is still at an early stage and does not have a marketed product franchise. Its position is therefore best understood as that of a small-cap clinical innovator competing in a crowded oncology research landscape. The company’s differentiation comes from the scientific novelty of its platforms, the intellectual property surrounding its vaccine and cell-therapy concepts, and the credibility of its academic and clinical partners. That makes the stock highly sensitive to trial results and financing conditions, while also giving it meaningful upside if one of the programs advances successfully. ([anixa.com](https://www.anixa.com/about?utm_source=openai)) Recent developments have been constructive. In 2025, Anixa reported positive Phase 1 data for its investigational breast cancer vaccine, stating that key primary endpoints were met and that immune responses were observed, supporting a move toward Phase 2 development. The company also announced a letter of intent with VERDI Solutions to develop personalized and off-the-shelf peptide vaccines for cancer patients. In 2026, Anixa highlighted encouraging survival observations from its ongoing ovarian cancer CAR-T Phase 1 study and disclosed that it received Mexican patent protection for its breast cancer vaccine technology. ([ir.anixa.com](https://ir.anixa.com/press-releases/detail/1107/anixa-biosciences-announces-positive-phase-1-data-for?utm_source=openai)) Overall, Anixa Biosciences Inc. is a United States biotech company listed on NASDAQ with a clear oncology mandate and a research-heavy profile. Its geographic footprint is still predominantly U.S.-centric, but its intellectual property and partnering strategy could support broader international relevance over time. For investors, the name represents a high-risk, high-upside exposure to cancer immunotherapy and vaccine development, with value creation tied to clinical milestones rather than current operating scale.